Log in to save to my catalogue

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated...

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1975015864

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

About this item

Full title

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2018-02, Vol.391 (10120), p.563-571

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

A safe, effective, and rapidly scalable vaccine against Zika virus infection is needed. We developed a purified formalin-inactivated Zika virus vaccine (ZPIV) candidate that showed protection in mice and non-human primates against viraemia after Zika virus challenge. Here we present the preliminary results in human beings.
We did three phase 1,...

Alternative Titles

Full title

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1975015864

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1975015864

Other Identifiers

ISSN

0140-6736,1474-547X

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(17)33106-9

How to access this item